Please login to the form below

Lidoderm

This page shows the latest Lidoderm news and features for those working in and with pharma, biotech and healthcare.

Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine.

Endo agrees $1.6bn deal to buy Paladin Labs

generic competition to Endo's Lidoderm (lidocaine) patch for post-shingles pain - and earnings per share (EPS) of $1.34, up from $1.28 a year earlier. ... Looking at the performance of Lidoderm, which fell 37 per cent, De Silva said that "prescription
Watson settles Lidoderm patent dispute with Endo

Watson settles Lidoderm patent dispute with Endo. Watson can now bring its generic version of the post-shingles pain patch to US market two years early. ... Once another generic product is launched following the 2015 patent expiry, however, Watson will
Global survey shows neuropathic pain under-diagnosed and under-served

Lidoderm is licensed to Endo for sale in the US and Versatis is licensed to Gruenenthal for the UK. ... For Endo in the US, Lidoderm racked up sales of USD 419 million in FY05.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Pharma deals during August 2013

The deal provides some protection for Endo's top-selling Lidoderm which accounted for 31 per cent of 2012 sales ($947.7m).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Add my company

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...